alexa Novel Antipsychotic Drugs Approved in 2015: Brexpiprazo
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Novel Antipsychotic Drugs Approved in 2015: Brexpiprazole, Cariprazine, Aripiprazole Lauroxil

Canan KUS*

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, 06100 Ankara, Turkey

Corresponding Author:
Canan KUS
Pharmaceutical Chemistry Department
Faculty of Pharmacy, Ankara University
06100 Tandogan Ankara, Turkey
Tel: +903122033075
Fax: +903122131081
E-mail: [email protected]

Received Date: June 14, 2016; Accepted Date: June 22, 2016; Published Date: June 27, 2016

Citation: Canan KUS (2016) Novel Antipsychotic Drugs Approved in 2015: Brexpiprazole, Cariprazine, Aripiprazole Lauroxil. Med chem (Los Angeles) 6:425-428. doi:10.4172/2161-0444.1000380

Copyright: © 2016 Canan KUS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Antipsychotic agents, highly benefit for the treatment of a range of psychiatric disorders and act by blocking dopamine receptors in the brain and interfering with dopaminergic transmission. Schizophrenia and mania which are psychosis are treated by antipsychotic drugs. These medicines are classified as typical or atypical antipsychotic drugs. The recently developed drugs which are named 'atypical antipsychotics' are useful in patients that do not respond to treatment with other typical antipsychotics. This review puts emphasis on the recent progress in therapeutically attractive piperazine derivatives being novel atypical antipsychotics that were apporved in 2015. Differences in safety-tolerability, affected receptors, activity, side effects are displayed in this review.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords